Resources
Being an empowered patient means understanding your treatment and the resources available to you. Take a moment to learn the facts about coverage and access to Prograf, the support provided by Astellas, and your right to receive the medication your doctor intends for you.
Undeniable Access
- 97% of Prograf prescriptions do not require prior authorization*1
- Average co-pay for Prograf is $24 at Tier 2 and $49 at Tier 3—88% of patients using the Prograf: Value Card will have their total monthly out-of-pocket costs fully covered†1
- Under Medicare Part B, there is no difference in patient out-of-pocket costs between Prograf and generic tacrolimus products2-4
With the Prograf: Value Card, save up to $200†
per month on your Prograf prescriptions.
The new Prograf: Value Keycard makes it even easier for you to save. The keycard attaches to your keychain, so savings are within easy reach each time you pick up your prescription.
Click Here for the Prograf: Value Card
Undeniable Support
- 100% of commercial insurance patients (outside of Massachusetts) are eligible for the Prograf: Value Card†
- Most pharmacies can obtain Prograf within one business day
Astellas Reimbursement ServicesSM (ARS)
ARS offers programs that can help remove financial barriers to receiving
Prograf, including assistance with benefit verification, prior authorization,
denied claims, and more.
Undeniable Right
- 100% of pharmacists are required to dispense Prograf when prescriptions are protected with "dispense as written" or other state-specific language1,5
Empower yourself with the facts, and ensure you receive the Prograf intended for you by your doctor. Click here to learn more.
Register for Transplant Experience today!
Be sure to visit TransplantExperience.com, where you'll find a wealth of resources to help you on the transplant journey ahead:
- Recipes for success
- Transplant stories
- Fresh articles and frequent updates
- Exclusive content for registered users
Not part of TransplantExperience.com? Join today!
*Based on analysis of patients covered by commercial plans who receive Prograf prescriptions.
†Excluding residents of Massachusetts and those who participate in Medicare, Medicaid, or any other federal- or state-funded pharmaceutical
References: 1. Data on file. 2. Centers for Medicare and Medicaid Services. Medicare & You 2010. http://www.medicare.gov/Publications/Pubs/pdf/10050.pdf. Published January 2010. Accessed June 10, 2010. 3. Centers for Medicare and Medicaid Services. Quarterly October 2007 quarterly average sales price (ASP) Medicare Part B drug pricing files and revisions to prior quarterly pricing files. Medicare Learning Network Matters, MM5710. http://www.cms.gov/MLNMattersArticles/downloads/MM5710.pdf. Effective October 1, 2007. Accessed June 10, 2010. 4. Centers for Medicare and Medicaid Services. Medicare claims processing manual. Chapter 17 — drugs and biologicals. Publication 100-04. http://www.cms.gov/manuals/downloads/clm104c17.pdf. Revised February 5, 2010. Accessed June 10, 2010. 5. Liow K. Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication. BMC Neurol. 2009;9:11.
